Enhanze Technology is Halozyme's proprietary drug delivery technology based on its recombinant human hyaluronidase (rHuPH20). rHuPH20 is an analogue of a human enzyme that temporarily clears space in
The FDA approved the prescription-to-over-the-counter (OTC) switch of MiraLAX in October. The FDA also ruled that MiraLAX will have marketing exclusivity for three years before any generic OTC
Pooled analyses from a number of phase III studies showed significant improvements in blood sugar control among patients in this age group when treated with Galvus without the
ReNeuron has successfully extracted stem cells from the developing brain of a 12 week old aborted fetus. The company plans to use the stem cells, known as ReN001,
Janumet is an investigational combination therapy of sitagliptin phosphate plus metformin. Janumet is designed to provide an additional treatment option for patients who need more than one oral
Indevus originally licensed worldwide rights to aminocandin from Sanofi-Aventis in 2003. Aminocandin is a member of the echinocandin class of anti-fungal compounds for the treatment of a broad
The funding is part of the organizations LEAD program to drive and accelerate the development of innovative and effective multiple myeloma treatments. The Multiple Myeloma Research Foundation (MMRF)
The positive results are from a phase II study where a statistically significant proportion of patients on active treatment obtained a 20% improvement of the American College of
Nalmefene did not demonstrate a statistically significant difference compared to placebo on the primary endpoint, a test of obsessive compulsive behavior, at the doses 20 mg and 40
The phase III European and Canadian psoriasis trial will be performed at thirty-six clinical centers in Canada, Germany, and Poland involving a total of 500 patients with moderate
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.